Real World Evidence study of isavuconazole efficacy and safety in treatment of invasive aspergillosis and mucormycosis in adults
Not Applicable
Completed
- Conditions
- Health Condition 1: J709- Respiratory conditions due to unspecified external agent
- Registration Number
- CTRI/2021/11/038216
- Lead Sponsor
- Pfizer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
1. Patients 18 years or older
2. Patients with diagnosis of invasive aspergillosis/invasive mucormycosis meeting the criteria for proven, probable or possible invasive mould disease as per the judgement of the treating physician and must have received Cresemba for at least 48h .
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of isavuconazole in the treatment of invasive aspergillosis and mucormycosis in adultsTimepoint: 6 weeks
- Secondary Outcome Measures
Name Time Method Effectiveness of isavuconazole in the treatment of invasive aspergillosis and mucormycosis in adultsTimepoint: 6 weeks